FluroTech CapEx/OCF

What does FluroTech do? FluroTech Ltd. commercializes fluorescence spectroscopy technology for pandemic defense through its subsidiary FluroTest Diagnostics Systems Ltd., which develops rapid antigen testing platforms for SARS-CoV-2 and other pathogens. The company targets high-traffic environments such as schools, hospitals, stadiums, and corporate campuses with its FluroTest system, utilizing robotics automation, biochemistry, fluorescence detection, and cloud computing to deliver results. FluroTest Diagnostics Systems Ltd. focuses on high-output rapid antigen testing for pandemic defense, serving sectors including healthcare, education, and public venues. The primary buyers of FluroTech's technology are institutions requiring rapid pathogen detection in high-traffic settings, including schools, colleges, hospitals, athletic venues, and corporate campuses. These organizations purchase the FluroTest system to manage pandemic risks through automated, high-volume testing solutions. The company's revenue streams are derived from the sale and deployment of its diagnostic platform across these institutional segments. FluroTech Ltd. leverages its subsidiary FluroTest Diagnostics Systems Ltd. to commercialize the PEDDP (pandemic and emerging disease defense platform), which is designed for environments like airports, cruise terminals, and shopping centers. The company's products are sold to entities needing rapid, scalable testing solutions for SARS-CoV-2 and other pathogens, with the focus on institutional rather than individual consumers. FluroTech is one of the most popular companies on Eulerpool.